The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome

Rheumatology (Oxford). 2016 Dec;55(12):2277-2278. doi: 10.1093/rheumatology/kew296. Epub 2016 Aug 21.

Authors

Sean M Murphy¹, James B Lilleker^{2

3}, Philip Helliwell⁴, Hector Chinoy^{5

3}

Affiliations

¹ Department of Rheumatology sean.murphy2@srft.nhs.uk.
² Greater Manchester Neurosciences Centre, Salford Royal NHS Foundation Trust, Salford.
³ NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester.
⁴ Section of Musculoskeletal Disease, Chapel Allerton Hospital, University of Leeds, Leeds, UK.
⁵ Department of Rheumatology.

PMID: 27550295
DOI: 10.1093/rheumatology/kew296

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / therapeutic use*
Arthritis / complications
Arthritis / diagnosis
Arthritis / drug therapy*
Biological Therapy / methods*
Female
Humans
Ligases / antagonists & inhibitors*
Lung Diseases, Interstitial / complications
Lung Diseases, Interstitial / diagnosis
Lung Diseases, Interstitial / drug therapy*
Magnetic Resonance Imaging
Myositis / complications
Myositis / diagnosis
Myositis / drug therapy*
Radiography
Syndrome

Substances

Antibodies, Monoclonal, Humanized
Ligases
tocilizumab